欧洲中部夏令时间2023年9月28日，欧洲内科肿瘤学会（ESMO）公布了即将召开的2023年ESMO大会上最为重磅的摘要LBAs（Late- Breaking Abstracts）题目及信息，覆盖Presidential Symposium（主席大会）、Proffered Paper Session（优选论文会议）、Mini Oral Session（简短口头摘要会议）所有口头摘要公布的会议。
据【肿瘤资讯】统计，今年中国研究入选LBAs总数高达14项，研究入选专家高达12位，远超2022年的7项研究、6位专家，达到历史新高！其中，北京大学肿瘤医院张小田教授、复旦大学附属肿瘤医院吴小华教授各有两项研究入选LBAs。详情请看下文（以下按照摘要号进行排序）！
LBA4 - Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC
讲者：中国香港 香港中文大学 龙浩锋教授（Herbert Ho Fung Loong）
LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)
讲者：中国武汉 华中科技大学同济医学院附属协和医院 林振宇教授
LBA26 - Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial
讲者：中国广州 中山大学肿瘤防治中心 丁培荣教授
LBA33 - A first-in-human phase 1 study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
讲者：中国上海 上海市肺科医院 周彩存教授
LBA36 - Efficacy and Safety of Senaparib as Maintenance Treatment in Patients with Newly Diagnosed Advanced Ovarian Cancer (FLAMES Study): A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
讲者：中国上海 复旦大学附属肿瘤医院 吴小华教授
LBA44 - Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer
讲者：中国上海 复旦大学附属肿瘤医院 吴小华教授
LBA58 - Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-IIIA NSCLC Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial
讲者：中国天津 天津医科大学肿瘤医院 岳东升教授
LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer
讲者：中国广州 中山大学肿瘤防治中心 赵泽锐教授
LBA69 - Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): a randomized multicenter study
讲者：中国北京 中国人民解放军总医院 胡毅 教授
LBA78 - Overall Survival of Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy: An Updated Analysis of RESOLVE Trial
讲者：中国北京 北京大学肿瘤医院 张小田教授
LBA79 - GEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase 3 study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
讲者：中国北京 北京大学肿瘤医院 张小田教授
LBA80 - Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus Chemo as First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Final Analysis Results of the RATIONALE-305 Study
讲者：中国广州 中山大学肿瘤防治中心 徐瑞华教授
LBA93 - EXTENTORCH: a randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)
讲者：中国长春 吉林省肿瘤医院 柳影教授
LBA96 - Roxadustat for Chemotherapy-Induced Anemia in Patients with Non-Myeloid Malignancies: A Randomized, Open-Label, Active-Controlled, Phase III Study
讲者：中国上海 上海市胸科医院 陆舜教授
2022年ESMO LBAs中国研究入选情况详见：2022 ESMO大会 | LBA之中国之声，医疗界顶级专家学者分享最新研究与实践！
（LBAs信息公布持续进行中，如有遗漏欢迎补充！）
https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session
排版编辑：肿瘤资讯-Bree
苏公网安备 32059002004080号
